Latest news

Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-3- and 6-month formulations – a new treatment for prostate cancer…

Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb study after record time patient randomisation

Clinical Update – Debio 025 in Hepatitis C – Debiopharm presents promising phase IIa results showing potent antiviral activity

Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate

Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue

Debiopharm Group et Debio R.P. accueillent Madame la Conseillère fédérale Doris Leuthard sur leur site de Martigny (Valais)

Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed…

Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer